Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Eighteen new option listings and one option delisting on January 21st » 08:30
01/21/21
01/21
08:30
01/21/21
08:30
ACTC

ArcLight Clean Transition

$27.88 /

-1.3 (-4.46%)

, ARQT

Arcutis Biotherapeutics

$28.27 /

-0.43 (-1.50%)

, CURI

CuriosityStream

$20.30 /

+0.36 (+1.81%)

, DLHC

DLH Holdings

$10.34 /

+0.26 (+2.58%)

, GXGX

GX Acquisition Corp.

$10.38 /

+ (+0.00%)

, HIMS

Hims & Hers

$0.00 /

+ (+0.00%)

, JG

Aurora Mobile

$3.84 /

+0.115 (+3.09%)

, JIH

Juniper Industrial Holdings

$12.11 /

+0.11 (+0.92%)

, KMPH

KemPharm

$6.08 /

+ (+0.00%)

, MWK

Mohawk Group

$23.97 /

+1.91 (+8.66%)

, RNLX

Renalytix AI

$22.46 /

+0.76 (+3.50%)

, TLS

Telos

$40.14 /

+0.44 (+1.11%)

, VCSH

Vanguard Short-Term Corporate Bond Index Fund

$83.13 /

-0.005 (-0.01%)

, VIH

VPC Impact Acquisition

$14.57 /

+0.095 (+0.66%)

, VMBS

Vanguard Mortgage-Backed Securities ETF

$54.05 /

+0.03 (+0.06%)

, VTC

Vought Aircraft

$93.24 /

+0.02 (+0.02%)

, WOOF

Petco

$26.05 /

-1.02 (-3.77%)

, OAC

Oaktree Acquisition

/

+

New option listings for…

New option listings for January 21st include ArcLight Clean Transition Corporation (Class A Stock) (ACTC), Arcutis Biotherapeutics Inc (ARQT), CuriosityStream Inc (Class A Stock) (CURI), DLH Holdings Corp. (DLHC), GX Acquisition Corporation (Class A Stock) (GXGX), Hims and Hers Health Inc (Class A Stock) (HIMS), Aurora Mobile Ltd (ADS) (JG), Juniper Industrial Holdings Inc (Class A Units) (JIH), KemPharm Inc (KMPH), Mohawk Group Holdings Inc (MWK), RenalytixAI PLC (ADS) (RNLX), Telos Corporation (TLS), Vanguard Short Term (VCSH), VPC Impact Acquisition Holdings (Class A Stock) (VIH), Vanguard Mortgage Backed Securities Bond (VMBS), Vanguard Total Corporate Bond (VTC), Vanguard Tax Exempt Bond ETF (VTEB), and Petco Health and Wellness Company Inc (Class A Stock) (WOOF). Option delistings effective January 21st include Oaktree Acquisition Corp (Class A Stock) (OAC).

ShowHide Related Items >><<
VIH VPC Impact Acquisition
$14.57 /

+0.095 (+0.66%)

TLS Telos
$40.14 /

+0.44 (+1.11%)

RNLX Renalytix AI
$22.46 /

+0.76 (+3.50%)

OAC Oaktree Acquisition
/

+

MWK Mohawk Group
$23.97 /

+1.91 (+8.66%)

KMPH KemPharm
$6.08 /

+ (+0.00%)

JIH Juniper Industrial Holdings
$12.11 /

+0.11 (+0.92%)

JG Aurora Mobile
$3.84 /

+0.115 (+3.09%)

HIMS Hims & Hers
$0.00 /

+ (+0.00%)

GXGX GX Acquisition Corp.
$10.38 /

+ (+0.00%)

DLHC DLH Holdings
$10.34 /

+0.26 (+2.58%)

CURI CuriosityStream
$20.30 /

+0.36 (+1.81%)

ARQT Arcutis Biotherapeutics
$28.27 /

-0.43 (-1.50%)

ACTC ArcLight Clean Transition
$27.88 /

-1.3 (-4.46%)

ACTC ArcLight Clean Transition
$27.88 /

-1.3 (-4.46%)

ARQT Arcutis Biotherapeutics
$28.27 /

-0.43 (-1.50%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
CURI CuriosityStream
$20.30 /

+0.36 (+1.81%)

01/12/21 Benchmark
CuriosityStream initiated with a Buy at Benchmark
01/06/21 B. Riley Securities
B. Riley downgrades CuriosityStream after 'puzzling' 95% stock rally
01/06/21 B. Riley Securities
CuriosityStream downgraded to Neutral from Buy at B. Riley Securities
12/21/20 Stifel
CuriosityStream downgraded to Hold from Buy at Stifel
DLHC DLH Holdings
$10.34 /

+0.26 (+2.58%)

03/27/20 Canaccord
DLH Holdings to benefit from increased virus-related research, says Canaccord
GXGX GX Acquisition Corp.
$10.38 /

+ (+0.00%)

HIMS Hims & Hers
$0.00 /

+ (+0.00%)

JG Aurora Mobile
$3.84 /

+0.115 (+3.09%)

JIH Juniper Industrial Holdings
$12.11 /

+0.11 (+0.92%)

KMPH KemPharm
$6.08 /

+ (+0.00%)

05/20/20 H.C. Wainwright
KemPharm price target lowered to $1.50 from $2.50 at H.C. Wainwright
MWK Mohawk Group
$23.97 /

+1.91 (+8.66%)

12/28/20 Sidoti
Mohawk Group initiated with a Buy at Sidoti
12/17/20 Alliance Global Partners
Alliance Global raises price target on '2021 top idea' Mohawk Group to $20
12/16/20 Oppenheimer
Mohawk Group initiated with an Outperform at Oppenheimer
12/02/20 Alliance Global Partners
Alliance Global Partners bullish on Mohawk as FBA roll up strategy continues
RNLX Renalytix AI
$22.46 /

+0.76 (+3.50%)

01/12/21 Stifel
Renalytix AI, Exact Sciences may benefit from final MCIT rule, says Stifel
08/11/20 JPMorgan
Renalytix AI initiated with a Neutral at JPMorgan
08/11/20 Stifel
Renalytix AI initiated with a Buy at Stifel
TLS Telos
$40.14 /

+0.44 (+1.11%)

01/19/21 Needham
Telos price target raised to $45 from $31 at Needham
01/12/21 B. Riley Securities
Telos price target raised to $40 from $34.50 at B. Riley Securities
12/23/20 Northland
Telos price target raised to $33 from $26 at Northland
12/14/20 Needham
Telos initiated with a Buy at Needham
VCSH Vanguard Short-Term Corporate Bond Index Fund
$83.13 /

-0.005 (-0.01%)

VIH VPC Impact Acquisition
$14.57 /

+0.095 (+0.66%)

VMBS Vanguard Mortgage-Backed Securities ETF
$54.05 /

+0.03 (+0.06%)

VTC Vought Aircraft
$93.24 /

+0.02 (+0.02%)

WOOF Petco
$26.05 /

-1.02 (-3.77%)

OAC Oaktree Acquisition
/

+

RNLX Renalytix AI
$22.46 /

+0.76 (+3.50%)

MWK Mohawk Group
$23.97 /

+1.91 (+8.66%)

DLHC DLH Holdings
$10.34 /

+0.26 (+2.58%)

ARQT Arcutis Biotherapeutics
$28.27 /

-0.43 (-1.50%)

  • 14
    Jan
  • 19
    Nov
  • 02
    Oct
  • 17
    Jul
  • 31
    Jan
VIH VPC Impact Acquisition
$14.57 /

+0.095 (+0.66%)

OAC Oaktree Acquisition
/

+

HIMS Hims & Hers
$0.00 /

+ (+0.00%)

WOOF Petco
$26.05 /

-1.02 (-3.77%)

VIH VPC Impact Acquisition
$14.57 /

+0.095 (+0.66%)

TLS Telos
$40.14 /

+0.44 (+1.11%)

MWK Mohawk Group
$23.97 /

+1.91 (+8.66%)

JG Aurora Mobile
$3.84 /

+0.115 (+3.09%)

CURI CuriosityStream
$20.30 /

+0.36 (+1.81%)

ARQT Arcutis Biotherapeutics
$28.27 /

-0.43 (-1.50%)

OAC Oaktree Acquisition
/

+

KMPH KemPharm
$6.08 /

+ (+0.00%)

VCSH Vanguard Short-Term Corporate Bond Index Fund
$83.13 /

-0.005 (-0.01%)

Wednesday
Hot Stocks
Arcutis to advance topical roflumilast foam into Phase 3 development » 09:03
01/20/21
01/20
09:03
01/20/21
09:03
ARQT

Arcutis Biotherapeutics

$28.69 /

-0.19 (-0.66%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced that it will advance its program to develop topical roflumilast foam as a treatment for seborrheic dermatitis into Phase 3 following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration. The Phase 3 program will consist of a single pivotal trial, which the Company anticipates initiating in the second or third quarter of 2021. Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor. Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective PDE4 inhibitor that Arcutis is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp, although it is usable in all areas of the body. Roflumilast has been approved by the FDA for systemic treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease since 2011. Roflumilast has shown greater potency than the two other FDA-approved PDE4 inhibitors. PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD. PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis or the systemic treatment of plaque psoriasis. Arcutis believes roflumilast foam has significant potential as a treatment for seborrheic dermatitis. In a recently completed Phase 2 study of roflumilast foam in seborrheic dermatitis, roflumilast foam demonstrated statistically significant improvement over the vehicle foam on the trial's primary endpoint, Investigator Global Assessment success, and multiple secondary endpoints including the reduction of itch. Once-daily roflumilast foam also demonstrated a favorable safety and tolerability profile. Additionally, other than a very small change in the formulation, roflumilast foam is identical to roflumilast cream, Arcutis' investigational topical cream PDE4 inhibitor, which has demonstrated symptomatic improvement and a favorable tolerability profile in clinical trials in plaque psoriasis, including chronic treatment of psoriasis, as well as encouraging results in atopic dermatitis. Arcutis is currently conducting a Phase 2 long-term safety study in seborrheic dermatitis. This is a multicenter, open-label study of roflumilast foam 0.3% applied once daily in adolescent and adult patients with seborrheic dermatitis and includes patients who were treated previously in the Phase 2 trial, as well as patients naive to treatment with topical roflumilast foam. Periodic clinic visits include assessments for clinical safety, application site reactions, and disease improvement, or progression.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$28.69 /

-0.19 (-0.66%)

ARQT Arcutis Biotherapeutics
$28.69 /

-0.19 (-0.66%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$28.69 /

-0.19 (-0.66%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$28.69 /

-0.19 (-0.66%)

Over a week ago
Hot Stocks
Arcutis initiaties Phase 3 clinical trials of topical roflumilast cream » 09:11
01/13/21
01/13
09:11
01/13/21
09:11
ARQT

Arcutis Biotherapeutics

$27.24 /

-0.43 (-1.55%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced that it has commenced pivotal Phase 3 clinical trials evaluating topical roflumilast cream as a potential treatment for atopic dermatitis. Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 inhibitor, which the Company is developing for plaque psoriasis and AD. The "INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis" 1 and 2 are identical Phase 3, parallel group, double blind, vehicle-controlled trials in which roflumilast cream 0.15% or vehicle is applied once daily for 4 weeks to subjects 6 years of age and older with mild to moderate AD involving greater than or equal to3% body surface area. In each trial, approximately 650 subjects are planned to be randomized 2:1 to either roflumilast cream 0.15% or matching vehicle cream. The primary endpoint of both trials is Investigator Global Assessment Success, defined as a Validated Investigator Global Assessment - Atopic Dermatitis score of 'clear' or 'almost clear' plus a 2-grade improvement from baseline at Week 4. Multiple secondary endpoints will also be evaluated, including itch as measured by the Worst Itch-Numerical Rating Scale as well as the proportion of subjects who attain at least a 75% reduction in the Eczema Area and Severity Index at Week 4. After completing INTEGUMENT-1 or -2, subjects may be eligible to enroll in a 12-month, open label extension study evaluating once daily roflumilast cream. The Company anticipates topline data from INTEGUMENT-1 and -2 in the second half of 2022. Arcutis also plans to initiate a third pivotal Phase 3 study, the "INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis in PEDiatric patients" shortly to evaluate roflumilast cream in subjects 2 to 5 years of age with mild to moderate AD.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$27.24 /

-0.43 (-1.55%)

ARQT Arcutis Biotherapeutics
$27.24 /

-0.43 (-1.55%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$27.24 /

-0.43 (-1.55%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$27.24 /

-0.43 (-1.55%)

Hot Stocks
Arcutis Biotherapeutics appoints Matthew Moore as CBO » 09:42
01/11/21
01/11
09:42
01/11/21
09:42
ARQT

Arcutis Biotherapeutics

$28.23 /

+0.29 (+1.04%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced that Matthew Moore has joined the company as Chief Business Officer. Most recently, he served as Vice President, Corporate Business Development and Alliance Management at Allergan, where he led worldwide strategy and business development for the company's $4B+ Medical Aesthetics business unit.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$28.23 /

+0.29 (+1.04%)

ARQT Arcutis Biotherapeutics
$28.23 /

+0.29 (+1.04%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$28.23 /

+0.29 (+1.04%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$28.23 /

+0.29 (+1.04%)

Over a month ago
Hot Stocks
Arcutis Biotherapeutics added to the Nasdaq Biotechnology Index » 09:27
12/21/20
12/21
09:27
12/21/20
09:27
ARQT

Arcutis Biotherapeutics

$28.96 /

-2.65 (-8.38%)

, NBI

Nasdaq Biotechnology Index

$0.00 /

+ (+0.00%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics (ARQT) announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020.

ShowHide Related Items >><<
NBI Nasdaq Biotechnology Index
$0.00 /

+ (+0.00%)

ARQT Arcutis Biotherapeutics
$28.96 /

-2.65 (-8.38%)

ARQT Arcutis Biotherapeutics
$28.96 /

-2.65 (-8.38%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
NBI Nasdaq Biotechnology Index
$0.00 /

+ (+0.00%)

ARQT Arcutis Biotherapeutics
$28.96 /

-2.65 (-8.38%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$28.96 /

-2.65 (-8.38%)

Conference/Events
Arcutis Biotherapeutics to host virtual investor day » 10:25
12/09/20
12/09
10:25
12/09/20
10:25
ARQT

Arcutis Biotherapeutics

$26.55 /

+0.34 (+1.30%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 9 at 11 am. Webcast Link

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$26.55 /

+0.34 (+1.30%)

ARQT Arcutis Biotherapeutics
$26.55 /

+0.34 (+1.30%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$26.55 /

+0.34 (+1.30%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$26.55 /

+0.34 (+1.30%)

Conference/Events
Arcutis Biotherapeutics to host virtual investor day » 04:55
12/09/20
12/09
04:55
12/09/20
04:55
ARQT

Arcutis Biotherapeutics

$26.21 /

-0.3 (-1.13%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 9 at 11 am. Webcast Link

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$26.21 /

-0.3 (-1.13%)

ARQT Arcutis Biotherapeutics
$26.21 /

-0.3 (-1.13%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$26.21 /

-0.3 (-1.13%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$26.21 /

-0.3 (-1.13%)

Hot Stocks
Arcutis says last patient completes final visit in DERMIS-1, DERMIS-2 trials » 09:18
12/07/20
12/07
09:18
12/07/20
09:18
ARQT

Arcutis Biotherapeutics

$26.00 /

-0.57 (-2.15%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced that the last participant has completed the 8-week treatment period in DERMIS-1 and DERMIS-2, the Company's pivotal Phase 3 clinical trials evaluating ARQ-151 as a potential topical treatment for plaque psoriasis. Arcutis recently announced positive results from its Phase 2 long-term safety study in plaque psoriasis, which support chronic use of roflumilast cream. In addition, The New England Journal of Medicine published results from the double-blind, randomized Phase 2b study of roflumilast cream in plaque psoriasis. The "Trials of PDE4 inhibition with Roflumilast for the Management of plaque PsoriasIS" One and Two are identical Phase 3 randomized, parallel, double-blind, vehicle-controlled, multi-national, multi-center studies in which roflumilast 0.3% cream or vehicle cream are applied once daily for 8 weeks to subjects age 2 years and above with mild, moderate or severe chronic plaque psoriasis involving between 2% and 20% body surface area. DERMIS-1 enrolled 439 subjects, and DERMIS-2 enrolled 442 subjects. The primary endpoint of the studies is Investigator Global Assessment Success, defined as an IGA score of clear or almost clear and at least a 2-grade improvement from baseline at week 8 on the IGA score. Multiple secondary endpoints will also be evaluated, including Intertriginous IGA Success, and improvements in Psoriasis Area Severity Index, itch as measured by the Worst Itch-Numerical Rating Scale and patient perceptions of symptoms as measured by the Psoriasis Symptoms Diary. The Company anticipates topline data from the Phase 3 studies in the first quarter of 2021 and, if positive, anticipates submission of its NDA to the FDA by the end of 2021.

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

Conference/Events
Arcutis Biotherapeutics to host virtual investor day » 18:11
12/04/20
12/04
18:11
12/04/20
18:11
ARQT

Arcutis Biotherapeutics

$26.00 /

-0.57 (-2.15%)

Virtual Investor Day to…

Virtual Investor Day to be held on December 9 at 11 am. Webcast Link

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$26.00 /

-0.57 (-2.15%)

Hot Stocks
Arcutis Biotherapeutics presents data on roflumilast cream study for psoriasis » 16:12
12/01/20
12/01
16:12
12/01/20
16:12
ARQT

Arcutis Biotherapeutics

$25.05 /

-1.95 (-7.22%)

Arcutis Biotherapeutics…

Arcutis Biotherapeutics announced positive results for the Phase 2 long-term safety study evaluating ARQ-151 0.3% as a potential once-daily chronic topical treatment for plaque psoriasis "We are delighted with the results from this study of patients receiving long-term treatment with roflumilast cream, which support our belief that roflumilast cream, unlike high potency steroids, can be used chronically," said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis' Chief Medical Officer. "We are encouraged that the efficacy and tolerability seen in this long-term study are consistent with the results seen in the double-blind Phase 2b study, and the unusually high proportion of patients who completed the full 52 weeks of treatment bodes well for real-world patient persistence. We believe there is a significant unmet need from patients and their dermatologists, who for too long have been forced to make trade-offs between efficacy, safety, and tolerability due to the significant shortcomings of existing topical treatments for psoriasis. Based on the strength of our clinical data to date, we believe that topical roflumilast has the potential to offer an ideal combination of efficacy comparable to a high potency steroid, the ability to use the drug chronically in any anatomical area, and a favorable safety and tolerability profile. We are hopeful that topical roflumilast, if approved, will help dermatologists and their patients to overcome these difficult clinical compromises. We look forward to the results from the ongoing DERMIS-1 and DERMIS-2 Phase 3 clinical trials of ARQ-151 in plaque psoriasis, which are anticipated in the first quarter of next year."

ShowHide Related Items >><<
ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
10/08/20 Truist
Arcutis Biotherapeutics initiated with a Buy at Truist
03/20/20 Cantor Fitzgerald
Arcutis dermatology potential remains underappreciated, says Cantor Fitzgerald
ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

  • 02
    Oct
  • 31
    Jan
ARQT Arcutis Biotherapeutics
$25.05 /

-1.95 (-7.22%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.